Company and Stock Identity

How GE HealthCare Connects to the Public Market

Company structure
Public company
Market access
Direct listing: Nasdaq: GEHC.
Stock name
GE HealthCare Technologies Inc.
Ticker and exchange
Nasdaq: GEHC
Research focus
Separate the value of AI software from the much larger imaging, ultrasound, patient-care, and pharmaceutical diagnostics businesses, then verify the authorization and evidence behind each product.

GE HealthCare became a separately traded public company in 2023 after its spin-off from General Electric.

Dated Market Snapshot

Oct 26, 2026

Last price
$71.98
Change
+0.74%
Previous close
$71.45
52-week high / low
$89.77/$58.75
Market cap
32,512,376,419

Automated from Nasdaq. Check the exchange or investor-relations page for the current price.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... GE HealthCare ... Company source

GE HealthCare will buy SOFIE Biosciences for 945 million dollars, and AI is not part of it

GE HealthCare announced on October 5, 2026 an agreement to acquire SOFIE Biosciences for 945 million dollars in cash, with closing expected in the first half of 2027. SOFIE runs a United States network of 15 contract manufacturing sites operating 21 cyclotrons, plus one development and manufacturing site focused on theranostics, and it makes and distributes the radiopharmaceuticals used in precision medicine imaging and therapy. GE HealthCare said SOFIE will keep operating as an independent manufacturing partner while joining its Pharmaceutical Diagnostics segment, and that it expects the deal to add to revenue growth, adjusted margin and adjusted earnings per share in the first full year of ownership. The announcement also names a pipeline asset called FAPI-74. Artificial intelligence is not mentioned in connection with the deal.

Why it matters: This is the single clearest reading of GE HealthCare's current priorities, and it points away from software. Nearly a billion dollars in cash is going into cyclotrons and delivery routes, because a PET tracer decays on the way to the scanner and no algorithm fixes that. For an investor who bought GE HealthCare as an imaging AI story, the honest takeaway is that the company is buying supply chain, and its AI work is still a research line rather than the place the capital goes.

... GE HealthCare ... Company source

GE HealthCare and Mass General Brigham will test AI for radiation therapy planning

GE HealthCare said on September 23, 2026 that it is expanding a research collaboration with a Mass General Brigham research team at Massachusetts General Hospital. The stated aim is a generative AI tool that could pull together structured clinical data and unstructured information, including clinical notes, images and treatment plans, so radiation oncology teams can reach a patient's treatment information faster. GE HealthCare names its existing Intelligent Radiation Therapy software as the starting point and points to possible later work across MR, CT and theranostics. The announcement describes work that could produce these capabilities rather than a cleared product, and states no regulatory status for the tool being explored.

Why it matters: A radiation oncology team loses real time hunting through records, so the problem being studied is a genuine one. The announcement is careful in a way worth noticing: it says what the collaboration will explore, not what it has proven, and it does not claim any regulatory status for the tool. A buyer should read it as a signal of where GE HealthCare is spending research money, not as something to put in next year's budget.

... GE HealthCare ... Company source

GE HealthCare launches software that warns a hospital 72 hours before it runs out of beds

GE HealthCare said on 15 September 2026 that it launched CareIntellect for Operations, a cloud software application that forecasts capacity pressure up to 72 hours ahead at unit, department and enterprise level and recommends actions on discharge, imaging, transfers and capacity. It runs on two GE HealthCare models, a Pressure Forecast model built from historical operations data plus live feeds from the records system, and an Estimated Day of Discharge model updated hourly. The Queen's Health Systems and Duke Health are named as the first health systems to implement it. GE HealthCare cites its own 2025 figures from existing Command Center customers of up to 20 million dollars in first-year cost savings, more than a one-day fall in average length of stay, and capacity for 19,000 more patients a year. The announcement does not mention FDA clearance.

Why it matters: Capacity is the constraint behind almost every other hospital problem, so a three-day warning is worth more than another dashboard if somebody acts on it. The honest caution is in the numbers: the savings and length-of-stay figures come from GE HealthCare's own Command Center customers rather than from this new product, which has two named evaluation sites and no published results yet. A forecast also only pays off where a hospital can actually change something in 72 hours, which usually means discharge planning and staffing, not bed count.

... GE HealthCare Investor Relations ... Investor relations

GE HealthCare sets out its AI and digital portfolio for HIMSS 2026

The company presented AI and digital products across its enterprise healthcare portfolio at HIMSS 2026.

Why it matters: GE HealthCare offers public-market exposure to a large healthcare technology business that includes AI. It is not a pure healthcare AI stock. Its AI exposure becomes more meaningful when orders, revenue, and customer results can be tied to the products on display.

... BrightHeart ... Company source

BrightHeart puts its fetal heart AI in GE HealthCare's Voluson store

BrightHeart said on 6 February 2026 that its B-Right AI platform is available through GE HealthCare's Voluson Solution Store. The company says the collaboration is meant to improve early detection of congenital defects and reduce uncertainty in reading a prenatal scan. It repeats that B-Right Views and B-Right Screen are each Class II FDA cleared and Class IIa CE marked under notified body 3022.

Why it matters: A scanner maker's own store is the cheapest way for a small vendor to reach the people already using that machine, and the Voluson line is widely used in obstetric ultrasound. It also makes the software easier to buy than to compare, so a department should still ask for the evidence rather than treating a listing as a recommendation. GE HealthCare distributing a product is not GE HealthCare validating it, and the clearances remain BrightHeart's.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Imaging science, software, AI, clinical applications, service engineering, regulatory affairs, product, sales, and hospital implementation.

Qualification signal: Role requirements vary from engineering degrees to clinical credentials and field-service training. Match the business unit and product before choosing a course or certification.

Check current roles at GE HealthCare. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

GE HealthCare appears on 9 cleared products in the federal 510(k) record, across 6 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources